CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy
An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated...
Saved in:
Published in | Theranostics Vol. 12; no. 16; pp. 6915 - 6930 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Ivyspring International Publisher Pty Ltd
01.01.2022
Ivyspring International Publisher |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors.
CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, >300 samples from six types of cancer, and in 49 cancer cell lines. A recombinant human/mouse chimeric anti-CDCP1 antibody (ch10D7) was labelled with
Zirconium or monomethyl auristatin E (MMAE) and tested in multiple pre-clinical cancer models including 36 cancer cell lines and three mouse xenograft models.
Analysis of CDCP1 expression indicates elevated CDCP1 expression in the majority of the cancers and restricted expression in normal human tissues. Antibody ch10D7 demonstrates a high affinity and specificity for CDCP1 inducing cell signalling via Src accompanied by rapid internalization of ch10D7/CDCP1 complexes in cancer cells
Zirconium-labelled ch10D7 accumulates in CDCP1 expressing cells enabling detection of pancreatic cancer xenografts in mice by PET imaging. Cytotoxicity of MMAE-labelled ch10D7 against kidney, colorectal, lung, ovarian, pancreatic and prostate cancer cells
, correlates with the level of CDCP1 on the plasma membrane. ch10D7-MMAE displays robust anti-tumor effects against mouse xenograft models of pancreatic, colorectal and ovarian cancer.
CDCP1 directed imaging agents will be useful for selecting cancer patients for personalized treatment with cytotoxin-loaded CDCP1 targeting agents including antibody-drug conjugates. |
---|---|
AbstractList | Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors.Methods: CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, > 300 samples from six types of cancer, and in 49 cancer cell lines. A recombinant human/mouse chimeric anti-CDCP1 antibody (ch10D7) was labelled with 89Zirconium or monomethyl auristatin E (MMAE) and tested in multiple pre-clinical cancer models including 36 cancer cell lines and three mouse xenograft models.Results: Analysis of CDCP1 expression indicates elevated CDCP1 expression in the majority of the cancers and restricted expression in normal human tissues. Antibody ch10D7 demonstrates a high affinity and specificity for CDCP1 inducing cell signalling via Src accompanied by rapid internalization of ch10D7/CDCP1 complexes in cancer cells. 89Zirconium-labelled ch10D7 accumulates in CDCP1 expressing cells enabling detection of pancreatic cancer xenografts in mice by PET imaging. Cytotoxicity of MMAE-labelled ch10D7 against kidney, colorectal, lung, ovarian, pancreatic and prostate cancer cells in vitro, correlates with the level of CDCP1 on the plasma membrane. ch10D7-MMAE displays robust anti-tumor effects against mouse xenograft models of pancreatic, colorectal and ovarian cancer.Conclusion: CDCP1 directed imaging agents will be useful for selecting cancer patients for personalized treatment with cytotoxin-loaded CDCP1 targeting agents including antibody-drug conjugates. An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors. CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, >300 samples from six types of cancer, and in 49 cancer cell lines. A recombinant human/mouse chimeric anti-CDCP1 antibody (ch10D7) was labelled with Zirconium or monomethyl auristatin E (MMAE) and tested in multiple pre-clinical cancer models including 36 cancer cell lines and three mouse xenograft models. Analysis of CDCP1 expression indicates elevated CDCP1 expression in the majority of the cancers and restricted expression in normal human tissues. Antibody ch10D7 demonstrates a high affinity and specificity for CDCP1 inducing cell signalling via Src accompanied by rapid internalization of ch10D7/CDCP1 complexes in cancer cells Zirconium-labelled ch10D7 accumulates in CDCP1 expressing cells enabling detection of pancreatic cancer xenografts in mice by PET imaging. Cytotoxicity of MMAE-labelled ch10D7 against kidney, colorectal, lung, ovarian, pancreatic and prostate cancer cells , correlates with the level of CDCP1 on the plasma membrane. ch10D7-MMAE displays robust anti-tumor effects against mouse xenograft models of pancreatic, colorectal and ovarian cancer. CDCP1 directed imaging agents will be useful for selecting cancer patients for personalized treatment with cytotoxin-loaded CDCP1 targeting agents including antibody-drug conjugates. Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors. Methods: CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, >300 samples from six types of cancer, and in 49 cancer cell lines. A recombinant human/mouse chimeric anti-CDCP1 antibody (ch10D7) was labelled with 89 Zirconium or monomethyl auristatin E (MMAE) and tested in multiple pre-clinical cancer models including 36 cancer cell lines and three mouse xenograft models. Results: Analysis of CDCP1 expression indicates elevated CDCP1 expression in the majority of the cancers and restricted expression in normal human tissues. Antibody ch10D7 demonstrates a high affinity and specificity for CDCP1 inducing cell signalling via Src accompanied by rapid internalization of ch10D7/CDCP1 complexes in cancer cells . 89 Zirconium-labelled ch10D7 accumulates in CDCP1 expressing cells enabling detection of pancreatic cancer xenografts in mice by PET imaging. Cytotoxicity of MMAE-labelled ch10D7 against kidney, colorectal, lung, ovarian, pancreatic and prostate cancer cells in vitro , correlates with the level of CDCP1 on the plasma membrane. ch10D7-MMAE displays robust anti-tumor effects against mouse xenograft models of pancreatic, colorectal and ovarian cancer. Conclusion: CDCP1 directed imaging agents will be useful for selecting cancer patients for personalized treatment with cytotoxin-loaded CDCP1 targeting agents including antibody-drug conjugates. |
Author | Tse, Brian W Puttick, Simon He, Yaowu Adams, Timothy E Cuda, Tahleesa J Rose, Stephen E Pearce, Lesley A Pajic, Marina Adams, Mark N Kryza, Thomas Lyons, Nicholas J Kwah, Kayden K X Khan, Tashbib Gough, Madeline Snell, Cameron E Sokolowski, Kamil A Hooper, John D |
AuthorAffiliation | 3 Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD, Australia 6 The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia 1 Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia 7 School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, QLD, Australia 5 Commonwealth Scientific and Industrial Research Organisation, Herston, QLD, Australia 2 Mater Health Services, South Brisbane, QLD, Australia 4 Commonwealth Scientific and Industrial Research Organisation Manufacturing, Parkville, VIC, Australia |
AuthorAffiliation_xml | – name: 3 Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD, Australia – name: 5 Commonwealth Scientific and Industrial Research Organisation, Herston, QLD, Australia – name: 6 The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia – name: 2 Mater Health Services, South Brisbane, QLD, Australia – name: 4 Commonwealth Scientific and Industrial Research Organisation Manufacturing, Parkville, VIC, Australia – name: 7 School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, QLD, Australia – name: 1 Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia |
Author_xml | – sequence: 1 givenname: Tashbib surname: Khan fullname: Khan, Tashbib organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 2 givenname: Nicholas J surname: Lyons fullname: Lyons, Nicholas J organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 3 givenname: Madeline surname: Gough fullname: Gough, Madeline organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 4 givenname: Kayden K X surname: Kwah fullname: Kwah, Kayden K X organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 5 givenname: Tahleesa J surname: Cuda fullname: Cuda, Tahleesa J organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 6 givenname: Cameron E surname: Snell fullname: Snell, Cameron E organization: Mater Health Services, South Brisbane, QLD, Australia – sequence: 7 givenname: Brian W surname: Tse fullname: Tse, Brian W organization: Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD, Australia – sequence: 8 givenname: Kamil A surname: Sokolowski fullname: Sokolowski, Kamil A organization: Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD, Australia – sequence: 9 givenname: Lesley A surname: Pearce fullname: Pearce, Lesley A organization: Commonwealth Scientific and Industrial Research Organisation Manufacturing, Parkville, VIC, Australia – sequence: 10 givenname: Timothy E surname: Adams fullname: Adams, Timothy E organization: Commonwealth Scientific and Industrial Research Organisation Manufacturing, Parkville, VIC, Australia – sequence: 11 givenname: Stephen E surname: Rose fullname: Rose, Stephen E organization: Commonwealth Scientific and Industrial Research Organisation, Herston, QLD, Australia – sequence: 12 givenname: Simon surname: Puttick fullname: Puttick, Simon organization: Commonwealth Scientific and Industrial Research Organisation, Herston, QLD, Australia – sequence: 13 givenname: Marina surname: Pajic fullname: Pajic, Marina organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia – sequence: 14 givenname: Mark N surname: Adams fullname: Adams, Mark N organization: School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, QLD, Australia – sequence: 15 givenname: Yaowu surname: He fullname: He, Yaowu organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 16 givenname: John D surname: Hooper fullname: Hooper, John D organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia – sequence: 17 givenname: Thomas surname: Kryza fullname: Kryza, Thomas organization: Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36276654$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkdtqGzEQhkVJadI0N32AIuhNU9hU8q5ON4F20xMEmovmWmil2bWMLbmSNuDH6ZtGdtKQCsQM6J9vNPO_RkchBkDoLSUXgjLyqSxDvBCSCvoCnVDZykbwjhw9y4_RWc4rUk9HFoqqV-i45QvBOetO0N_-9gu-ihvjQ9PHUGr0YcI3KRbwAVP8ob_qb-g59hkbnEzxMZg1LiZNUPAYEy5LwA7uYB23GwgFxxH7jZn2lJKMhVQLg6u3-CG6XePSPGEbw2qeTIF8YFgTqrBiCth9h0NFBSez3b1BL0ezznD2GE_R7bevv_sfzfWv7z_7z9eN7QgvjRs6aWXHHFeiBUtAGjYOatFKGKkzTA7WgFLKWWEXVg6KtUa4gVDCueEO2lN0-cDdzsMGnK2zJLPW21SnSTsdjdf_vwS_1FO804rVXVJSAe8fASn-mSEXvYpzqtvKum6bSEGYZFX18UFlU8w5wfjUgRK9d1TvHdUHR6v43fM_PUn_-dfeA0lboZc |
CitedBy_id | crossref_primary_10_3389_fonc_2023_1259784 |
ContentType | Journal Article |
Copyright | The author(s). 2022. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The author(s) 2022 |
Copyright_xml | – notice: The author(s). – notice: 2022. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The author(s) 2022 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 5PM |
DOI | 10.7150/thno.78171 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1838-7640 |
EndPage | 6930 |
ExternalDocumentID | 10_7150_thno_78171 36276654 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 53G 5VS 7X7 8FI 8FJ ABUWG ADBBV ADRAZ AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CGR CUY CVF DIK ECM EIF FYUFA GROUPED_DOAJ HMCUK HYE KQ8 M48 M~E NPM O5R O5S OK1 PGMZT PIMPY RPM UKHRP AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQQKQ PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c406t-db48c845d6973ec0e8a5fb9238ef1da58bcae999dc7c2c8b953a7db01066a6de3 |
IEDL.DBID | RPM |
ISSN | 1838-7640 |
IngestDate | Tue Sep 17 21:31:39 EDT 2024 Thu Oct 10 16:49:15 EDT 2024 Fri Aug 23 00:48:33 EDT 2024 Sat Sep 28 08:17:28 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Keywords | theranostics cancer CDCP1 antibody-drug conjugate receptor |
Language | English |
License | The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c406t-db48c845d6973ec0e8a5fb9238ef1da58bcae999dc7c2c8b953a7db01066a6de3 |
Notes | Competing Interests: Thomas Kryza, Simon Puttick, Yaowu He and John D. Hooper are inventors on a patent covering the use of antibody 10D7 used in this study. No potential conflicts of interest were disclosed by the other authors. Authors with equal contributions. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576610/ |
PMID | 36276654 |
PQID | 2760870585 |
PQPubID | 5263173 |
PageCount | 16 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9576610 proquest_journals_2760870585 crossref_primary_10_7150_thno_78171 pubmed_primary_36276654 |
PublicationCentury | 2000 |
PublicationDate | 2022-01-01 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia – name: Wyoming – name: Sydney |
PublicationTitle | Theranostics |
PublicationTitleAlternate | Theranostics |
PublicationYear | 2022 |
Publisher | Ivyspring International Publisher Pty Ltd Ivyspring International Publisher |
Publisher_xml | – name: Ivyspring International Publisher Pty Ltd – name: Ivyspring International Publisher |
SSID | ssj0000402919 |
Score | 2.3495922 |
Snippet | An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on... Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein... Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 6915 |
SubjectTerms | Animals Antigens, Neoplasm Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Binding sites Cancer therapies Cell Adhesion Molecules Cell Line, Tumor Colorectal cancer Colorectal Neoplasms Cytotoxicity Cytotoxins Experiments Female Flow cytometry Humans Immunoconjugates - pharmacology Ligands Male Mice Microscopy Monoclonal antibodies Ovarian cancer Patients Payloads Prostate cancer Research Paper RNA, Messenger Tumors Xenograft Model Antitumor Assays Zirconium |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwELYKvcChKuXRbWk1UjnAwRDnYccnRJciVAnEgZX2FvkVCBIJ3c0e-Dn8U8ZOdmFB6iGnJJNI38TzzWT8DSF7WvFIushSzZOIpkZwqpxLqMpyg3Qic93MyItLfj5K_46zcV9wm_ZtlfM1MSzUtjG-Rn4UCx6hbyG7PX74R_3UKP93tR-hsUI-shhDOfqzGItFjQUdNJZMdqqkAqnPUXtbN4ciZ4Itx6F35PJtj-SroHP2mXzq2SKcdPBukA-u_kLWX2kIbpKn4eg3nDb3mOFTLzXVTXyAK6-_UNXAYH94OrxiB1BNQcGkr_1B1wEOSFkBKSDYl94haEqo7sPwIsB3MsgPQdUWj7bSjX2kdjK7AUyj72a-BDcNNox3ngmaaUNrVx3u6PZ2PW6R0dmf6-E57ecuUIPhvaVWp7nJ08xyKRJnIperrNTIBHNXMosoaqMcEktrhIlNrmWWKGG1zy654tYl22S1bmr3lYApUyZNUsq4LFMZcWWkQBLEklxomZRsQH7NUSgeOnmNAtMSj1XhsSoCVgOyOweo6D-xafHiEAOy02G1MIFRWfixygMillBcXOBFtZfP1NVtENeWmIAhpfz2_0d-J2ux3wcRajG7ZLWdzNwPZCet_hlc8BnDgunU priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LTtwwFLUQ3cACtUDLtICuBAu68JCnH6uqDCCEBGLBSOwiv1KCIGkzGanzOf3TXicZYACxyCqxE_k4vudY1-cSsq8VC6QLLNUsDmhiOKPKuZiqVBikE6nrakZeXLKzcXJ-k94skXn9zn4AJ29KO19PalzfD__-mf3AHx7565AjnzlsbstqyEXoj5J_iDAi-tSui57mtysyiiQZys6d9EWTxXj0imS-zJV8FnxOP5K1njXCzw7mT2TJletk9ZmX4Ab5NxofwXH1gEqfesuprvIDXHkfhqKEEA5Gx6Or8DsUE1BQ93uA0GWCA1JXQCoI9imHCKocioe2iBHgNxnkiaBKi1dT6MrOqK2nvwDl9N3Ub8VN2j6Mn0Q1dtO0KV5l26I74zXbJOPTk-vRGe3rL1CDYb6hVifCiCS1TPLYmcAJleYaGaFweWgRTW2UQ4JpDTeREVqmseJWe5XJFLMu_kyWy6p0WwRMnoTSxLmM8jyRAVNGciRDYSy4lnEeDsjeHIXsd2ezkaE88VhlHqusxWpAtucAZfOZkkWcBbjooOwZkC8dVo9dYHTmvrzygPAFFB8f8Obai3fK4rY12ZYoxJBafn3_ld_ISiT82Xy_J7NNlpt66naQpTR6t52C_wEZHewj priority: 102 providerName: Scholars Portal |
Title | CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36276654 https://www.proquest.com/docview/2760870585 https://pubmed.ncbi.nlm.nih.gov/PMC9576610 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV27btswFCWSdGmHoO-4TQ0C7dAOtEVL4mNslARBAQdGUQPeBL7UqKipwJaHfE7_tJeUnNrNlkFaJBICzhXvOcTluQh90ool0iWWaJYmJDOcEeVcSlQuDNCJ3HU9I6fX7GqefVvkiwOUb8_CxKJ9o-uR_70c-fom1lbeLs14Wyc2nk0LCSQZ0v74EB1C-t2R6HH5BUUkqeysSDnwnXF745sRF5TT_eTzgFH-Xxi5k2kun6PjniLir92nvEAHzr9Ez3aMA1-hP8X8DJ83S5D1JPhLdW0e8CyYLtQeU_y5OC9m9Auu11jhVb_hh7uybww8FQPvw_ZfwRBuKlwvY8ciDN9kgBRi5S1cba0be0fsavMTg3b-tQn7bus4hwkRs4Jp2ljP5eOI7kDX3Ws0v7z4UVyRvtkCMZDTW2J1JozIcsskT51JnFB5pYH-CVdRC9BpoxywSWu4mRihZZ4qbnWQlEwx69I36Mg33p0gbKqMSpNWclJVmUyYMpID86Gp4FqmFR2gj1sUytvOU6MELRKwKgNWZcRqgE63AJX9f7UuJ5wlsMKAxhmgtx1W91NAKuahl_IA8T0U718ITtr7TyDAoqN2H1DvHj3yPXo6Ceci4t7MKTpqVxv3AdhKq4cQows-RE_OLq5n34dR88N9molhjNu_TZz1aA |
link.rule.ids | 230,314,727,780,784,864,885,2221,12056,21388,24318,27924,27925,31719,33744,43310,43805,53791,53793,73745,74302 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB5BegAOqLwDLYwEBzgs9fq13hNq01YB2ihCjdSbtS9TI9UuiXPoz-GfMms7aVMkDj7ZHlv6xjvfjGe_AfigVRpIF1im0yhgsREpU85FTCWZITqRuG5m5OkkHc_ib-fJeV9wW_Rtlas1sV2obW18jXwvFGlAvkXs9svVb-anRvm_q_0Ijfuw5ZXTkwFsHRxNpj_WVRZy0VBy2emSCiI_e81FVX8WGRd8MxL9Qy_vdkneCjvH2_C454u43wH8BO656ik8uqUi-Az-jGYHeFhfUo7PvNhUN_MBp16BoayQ48fR4WjKP2G5QIXzvvqHXQ84EmlFIoFob7qHsC6wvGzHFyG9kyGGiKqydDSlru01s_PlT6RE-tfSF-EWrQ3j3WdOZpq2uatq7-h2d10_h9nx0dlozPrJC8xQgG-Y1XFmsjixqRSRM4HLVFJo4oKZK7glHLVRjqilNcKEJtMyiZSw2ueXqUqti17AoKor9wrQFDGXJipkWBSxDFJlpCAaxKNMaBkVfAjvVyjkV53ARk6Jiccq91jlLVZD2FkBlPcf2SK_cYkhvOywWpuguCz8YOUhiA0U1xd4We3NM1V50cprS0rBiFS-_v8j38GD8dnpSX7ydfL9DTwM_a6ItjKzA4NmvnS7xFUa_bZ3yL_c7u4q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BKiE4IJ4lpcBIcIDDEq8fu94Tokmj8ooiRKTerH2ZGql2mziH_hz-KbP2Jm1A4uCT7bGlb7zzzXh2PkLeaMUj6SJLNU8imhrBqXIuoSrLDdKJzPWakd9m_GSRfj7NTkP_0yq0VW7WxG6hto3xNfJRLHiEvoXsdlSGtoj5ZPrh4pJ6BSn_pzXIadwmexgVo3hA9o6OZ_Pv24oLumssmexnlAokQqP2rG7ei5wJthuV_qGaf3dM3ghB0wfkfuCO8LEH-yG55epH5N6NiYKPye_x4ggmzTnm-9QPnur1H2DupzFUNTB4O56M5-wdVCtQsAyVQOj7wQEJLCAhBHvdSQRNCdV5J2UE-E4G2SKo2uLRVrqxV9Qu1z8Bk-pfa1-QW3U2jHelJZppu0avuruj3-l19YQspsc_xic0qDBQg8G-pVanucnTzHIpEmcil6us1MgLc1cyi5hqoxzSTGuEiU2uZZYoYbXPNbni1iVPyaBuaveMgClTJk1SyrgsUxlxZaRASsSSXGiZlGxIXm9QKC76YRsFJikeq8JjVXRYDcnhBqAifHCr4to9hmS_x2prAmO08CLLQyJ2UNxe4Eds756pq7Nu1LbEdAwJ5sH_H_mK3EFfLL5-mn15Tu7GfoNEV6Q5JIN2uXYvkLa0-mXwxz-QjfJX |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CUB+Domain-Containing+Protein+1+%28CDCP1%29+is+a+rational+target+for+the+development+of+imaging+tracers+and+antibody-drug+conjugates+for+cancer+detection+and+therapy&rft.jtitle=Theranostics&rft.au=Khan%2C+Tashbib&rft.au=Lyons%2C+Nicholas+J&rft.au=Gough%2C+Madeline&rft.au=Kayden+K.X.+Kwah&rft.date=2022-01-01&rft.pub=Ivyspring+International+Publisher+Pty+Ltd&rft.eissn=1838-7640&rft.volume=12&rft.issue=16&rft.spage=6915&rft_id=info:doi/10.7150%2Fthno.78171&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1838-7640&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1838-7640&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1838-7640&client=summon |